Shire

Fiercebiotech | September 11, 2017

Shire has posted positive results for its late-stage hereditary angioedema candidate SHP616 against a dummy treatment. The biopharma’s subcutaneous C1 esterase inhibitor significantly lowered hereditary angioedema (HAE) monthly attack rate against placebo in the pivotal phase 3. Data from the Sahara test show that median HAE attack reduction hit 79% from day 0, and 85% from day 14. Shire also found that 38% of patients were HAE attack free while on its med....

biotech | May 03, 2017

Shire’s proposed 400-job plant at Dunboyne is fully on track, with the company moving to put fears to rest that work on the new facility would stop or that the project would continue on a smaller scale...

biopharmadive | July 10, 2017

In an unexpected move, Shire International has secured an injunction in a Hamburg, Germany court against Roche for the Swiss pharma's as yet unmarketed hemophilia drug, emicizumab. The injunction claims Roche is disseminating "inaccurate and misleading characterization of the serious adverse events that occurred in the HAVEN 1 Phase 3 trial of emicizumab, as well as misinformation about "the appropriate management of breakthrough bleeds uncontrolled by emicizumab....

Labiotech.eu | January 28, 2020

A Swiss research group has developed tiny plastic particles that could carry gene therapies to the center of the cell with less risk of getting attacked by the immune system than conventional gene therapies. The majority of gene therapies in use today are delivered to the DNA of target cells using viral vectors. While efficient at their job, viral vectors can risk triggering the immune system to destroy them. This can lead to the therapy becoming ineffective....